TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early relapse stage II/III BRAF V600E-mutated CRCS. Boku,H. Satake,T. Ohta,S. Mitani, K. Kawakami,T. Matsumoto,E. Yamazaki, H. Hasegawa,T. Ikoma, M. Uemura, T. Yamaguchi, Y. Ishizuka,Y. Kurokawa,D. Sakai,H. Kawakami,T. Shimokawa, T. Tsujinaka,T. Kato,T. Satoh,Y. KagawaANNALS OF ONCOLOGY(2022)引用 0|浏览6暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要